1. Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
   Anke E. M. van Erp et al, 2017, Targ Oncol CrossRef
2. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer
   Maria Tsoli et al, 2018, Cancer Biology & Therapy CrossRef
3. ALK^ATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma.
   Bu-Shu Xu et al, 2020, Oncogene CrossRef
4. GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas
   Toshiaki Haraguchi et al, 2016, PLoS ONE CrossRef
5. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
   Emmy D.G. Fleuren et al, 2017, Cancer Res CrossRef
6. Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis
   Chuanxi Zheng et al, 2022, BMC Musculoskelet Disord CrossRef
7. ALK, NUT, and TRK Do Not Play Relevant Roles in Gastric Cancer—Results of an Immunohistochemical Study in a Large Series
   Marie-Isabelle Glückstein et al, 2022, Diagnostics CrossRef
8. ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights
   Minsun Jung et al, 2022 CrossRef